All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Decision-making algorithm for the management of moderate-to-severe psoriasis: Consensus guidelines from the Center of Evidence of the French Society of Dermatology
| The Center of Evidence of the French Society of Dermatology developed consensus-based guidelines for the treatment of adult patients with moderate-to-severe psoriasis.1 These guidelines follow the 2019 French guidelines, and incorporate the newer interleukin (IL)-23 and IL-17 inhibitors. The guidelines were developed by 35 experts using the Delphi method, and were published in Annales de Dermatologie et de Vénéréologie by Poizeau et al.1 |
| Key learnings |
| The Center of Evidence of the French Society of Dermatology provides a decision-making algorithm, based on consensus statements, for treatment selection for adult patients with moderate-to-severe psoriasis. |
| Methotrexate remains the first-line systemic treatment for moderate-to-severe plaque psoriasis without any contradictions, supported by 89% of experts, reinforcing its role in clinical practice. |
| Newly available IL-17 and IL-23 inhibitors, such as guselkumab, risankizumab, ixekizumab, and secukinumab, were recommended by 91%, 85%, 83%, and 82% of experts, respectively, for second-line treatment of patients with non-biologic treatment failure or intolerance, and are favored over tumor necrosis factor (TNF) inhibitors and IL-12/23 inhibitors, reflecting their superior efficacy in recent clinical trials. TNF inhibitors were recommended for patients with cardiovascular risk factors. |
| Cyclosporine is recommended for rapidly progressive forms of psoriasis, such as pustular and erythrodermic psoriasis, with specific endorsement for pregnant patients or those planning pregnancy, emphasizing its value in urgent or specific patient scenarios. |
| This decision-making algorithm provides a structured approach to the management of moderate-to-severe psoriasis, ensuring clinicians can integrate the latest consensus into personalized patient care and improved therapeutic outcomes. |
- Poizeau F, Leducq S, Fardet L, et al. Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm. Ann Dermatol Venereol. Online ahead of print. DOI: 10.1016/j.annder.2024.103287
Your opinion matters
4 votes - 19 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox